ID1 and neoplasm: At day 14 after treatment initiation, we observed a very significant decrease in tumor growth in Id1 knockout mice treated with an anti-PD1 monoclonal antibody (Id1+/+/anti-PD-1, p = 0.0029; Id1+/+/DPBS, p < 0.0001) (Figure 6A).